{"prompt": "['Sponsor: APGD', 'ISN/Protocol 7465-CL-0301', 'EudraCT number 2017-003344-21', '- CONFIDENTIAL -', 'Grade', 'Assessment Standard', '1-Mild', 'Asymptomatic or mild symptoms, clinical or diagnostic', 'observations noted; intervention not indicated.', '2-Moderate', 'Local or noninvasive intervention indicated.', '3-Severe', 'Medically significant but not immediately life threatening,', 'hospitalization or prolonged hospitalization.', '4-Life Threatening', 'Life threatening consequences, urgent intervention indicated', '5-Death', 'Death related to AE', 'The investigator will use the following definitions to rate the severity of each adverse event', 'Mild:', 'No disruption of normal daily activities', 'Moderate: Affect normal daily activities', 'Severe:', 'Inability to perform daily activities', '5.6.5 Reporting of Serious Adverse Events', 'The collection of AEs and the expedited reporting of SAEs will start following receipt of the', 'informed consent and will continue to 30 days after last administration of study drug.', 'In the case of a SAE, the investigator must contact the sponsor by fax or email immediately', '(within 24 hours of awareness).', 'The investigator must complete and submit a SAE worksheet containing all information that', 'is required by local and/or regional regulations to the sponsor by email or fax immediately', '(within 24 hours of awareness). If the faxing of an SAE Worksheet is not possible or is not', 'possible within 24 hours, the local drug safety contact should be informed by phone.', 'For sites located in Japan:', 'In the case of a serious adverse event (SAE), the investigator or sub-investigator must report', 'to the head of the study site and must contact the sponsor (directly or via the delegated CRO)', 'by telephone or fax immediately (within 24 hours of awareness).', 'The investigator should complete and submit JUTOKUNA YUUGAIJISHOU HOUKOKUSHO', 'containing all information that is required by the Regulatory Authorities to the sponsor (directly', 'or via the delegated CRO) by fax immediately (within 24 hours of awareness) and to the head of', 'the hospital. If the faxing of JUTOKUNA YUUGAIJISHOU HOUKOKUSHO is not possible', 'or is not possible within 24 hours, the sponsor should be informed by phone.', 'For contact details, see [Section', \"II Contact Details of Key Sponsor's Personnel].\", '14 Sep 2020', 'Astellas', 'Page 75 of 143', 'Version 4.0 Incorporating Substantial Amendment 3']['Sponsor: APGD', 'ISN/Protocol 7465-CL-0301', 'EudraCT number 2017-003344-21', '- CONFIDENTIAL -', 'Please Fax or email the SAE Worksheet for Japan (JUTOKUNA YUUGAIJISHOU', 'HOUKOKUSHO) to:', 'PAREXEL International', 'Clinical Development', 'Fax number +81-(0)3-6888-1654', 'or', 'Astellas Pharma Inc. - Japan', 'JP Clinical Development,', 'Fax number +81-(0)3-3243-5737', 'If there are any questions, or if clarification is needed regarding the SAE, please contact the', \"sponsor's Medical Monitor/Study Physician or his/her designee Section\", 'II', 'Contact Details of', \"Key Sponsor's Personnel].\", 'Follow-up information for the event should be sent promptly (within 2 days of the initial', 'notification.', 'For sites located in all other countries:', 'Please fax or email the SAE worksheet for all other country sites to:', 'Astellas Pharma Global Development, Inc.', 'Pharmacovigilance', 'North America Fax number 1-888-396-3750', 'Alternate North America Fax number 1-847-317-1241', 'International Fax number +44-800-471-5263', 'Email: safety-us@astellas.com', 'If there are any questions, or if clarification is needed regarding the SAE, please contact the', \"sponsor's Medical Monitor/Study Physician or his/her designee [Section II Contact Details of\", \"Key Sponsor's Personnel].\", 'Follow-up information for the event should be sent promptly (within 7 days of the initial', 'notification.', 'Full details of the SAE should be recorded on the medical records, SAE/Special Situation', 'Worksheet and on the (e)CRF.', 'The following minimum information is required:', 'International Study Number (ISN)/Study number,', 'Subject number, sex and age,', 'The date of report,', 'A description of the SAE (event, seriousness criteria),', 'Causal relationship to the study drug (including reason), and', 'The drug provided (if any)', \"The sponsor or sponsor's designee will submit expedited safety reports (e.g., Investigational\", 'New Drug [IND] Safety Reports, Council for International Organizations of Medical', '14 Sep 2020', 'Astellas', 'Page 76 of 143', 'Version 4.0 Incorporating Substantial Amendment 3']\n\n###\n\n", "completion": "END"}